Navigation Links
Amgen Announces Evolocumab (AMG 145) Results From First 52-Week Study Of A PCSK9 Inhibitor To Reduce LDL Cholesterol
Date:11/19/2013

tins (GAUSS-2), as a stand-alone treatment in patients with hyperlipidemia (MENDEL-2), and in patients whose elevated cholesterol is caused by genetic disorders called heterozygous (RUTHERFORD-2) and homozygous (TESLA and TAUSSIG) familial hypercholesterolemia.

Five studies of evolocumab will provide long-term safety and efficacy data, including the FOURIER (Further Cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) study, which will assess whether treatment with evolocumab compared to placebo reduces recurrent cardiovascular events in approximately 22,500 patients with cardiovascular disease.

Additional information about clinical trials of evolocumab can be found at www.clinicaltrials.gov.

About Evolocumab
Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9).1 PCSK9 is a protein that targets LDL receptors for degradation and thereby reduces the liver's ability to remove LDL-C, or "bad" cholesterol, from the blood.6 Evolocumab, being developed by Amgen scientists, is designed to bind to PCSK9 and inhibit PCSK9 from binding to LDL receptors on the liver surface. In the absence of PCSK9, there are more LDL receptors on the surface of the liver to remove LDL-C from the blood.1

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
2. Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013
3. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
4. Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
5. Amgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus
6. Amgen And Servier Complete Product Collaboration Transaction
7. Amgen Announces 2013 Third Quarter Dividend
8. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
9. Amgen And Servier Announce Product Collaboration
10. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
11. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Research and Markets ... Synthetic Biology Market 2014-2018" report to their offering. ... The term synthetic biology covers the designing and engineering ... well as the redesigning of natural biological systems that ... be a form of extreme genetic engineering because it ...
(Date:7/28/2014)... & Boston, MA (PRWEB) July 28, 2014 ... agreements with two researchers to further develop potential treatments ... malignant brain tumor, in combination with their patented vaccine ... ITI and Duke University, are based on the work ... Division of Neurosurgery at The Preston Robert Tisch Brain ...
(Date:7/28/2014)... 2014 The global market for biotechnology ... according to a new study by Grand View Research, ... for effective vaccines and drugs in an attempt to ... is expected to drive market demand over the next ... productivity via the use of genetically engineered seeds is ...
(Date:7/28/2014)... The National Model Aviation Museum, located at ... to announce that it has been granted full civilian ... States Air Force. , The certification is the culmination ... spring with an on-site inspection by Sarah Sessions, Museum ... National Museum of the United States Air Force ...
Breaking Biology Technology:Global Synthetic Biology Market 2014-2018 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4AMA’s National Model Aviation Museum Granted Full Civilian Museum Certification by the National Museum of the United States Air Force 2
... for Design Excellence and Patient Ease-of-Use, BROOKFIELD, ... ) today won the 2008 Medical Design Excellence ... device. The Genesis DM won in the,rehabilitation and ... remote patient monitoring device is,ideal for both the ...
... April 7, 2008 Replikins Ltd. has found that ... has recently,increased to 7.6 (plus/minus 1.4), its highest level ... A rising Replikin Count of a particular,influenza strain, indicating ... has been followed consistently by an outbreak of the ...
... 7, 2008 A,cross-disciplinary research team at the University ... microscopic drug research platform can,produce the chemical reactions needed ... enzyme on a tiny "biochip" created to mimic,the environment ... normally,would. This means that the researchers can proceed to ...
Cached Biology Technology:Honeywell HomMed Wins 2008 Medical Design Excellence Award for Genesis DM Remote Care Device 2Honeywell HomMed Wins 2008 Medical Design Excellence Award for Genesis DM Remote Care Device 3H1N1 Influenza Virus With Highest Replikin Count(TM) Since the 1918 Pandemic Identified in the U.S. and Austria 2U-Md. Researchers Report Advance in Biological Microfactories for Drug Research 2U-Md. Researchers Report Advance in Biological Microfactories for Drug Research 3U-Md. Researchers Report Advance in Biological Microfactories for Drug Research 4
(Date:7/28/2014)... calls himself the bug hunter, but the target of ... found and identified with special methods and instruments. Benjamin ... Veterinary Diagnostic Laboratory at Kansas State University, recently published ... G, which is an important find in the United ... but didn,t know what it was," Hause said. "We ...
(Date:7/28/2014)... 2014)The Brain & Behavior Research Foundation today announced ... Prizes, recognizing exceptional clinical and basic research by ... Young Investigator Grants. The grants enable early career ... psychosocial research for the prevention, early detection, treatment, ... in four people. , Six young scientistswinners of ...
(Date:7/28/2014)... to prevent and treat HIV infection has been problematic ... molecules can arouse as they get rid of the ... Weizmann Institute and the National Institutes of Health (NIH) ... interferons around the time of infection could ... Their research appeared in Nature . , ...
Breaking Biology News(10 mins):Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 2The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 4Interfering with interferon 2
... working on the fundamental biological processes of plants could ... many parts of the world. Using model plant species, ... uncovered one of the processes used by the plants ... discoveries are now being applied to improve the productivity ...
... geochemists from the University of Southern California and Rice ... that could power spy drones that fit in the ... long been interested in micro-scale air vehicles ?some as ... the lack of a suitable, compact power source. With ...
... at the Max Planck Institute of Biochemistry in Martinsried, ... that blocking blood vessel development in a tumour slows ... principle led to the development of SUTENT®, whose active ... use in the United States, and it is expected ...
Cached Biology News:Sun protection for plants 2USC, Rice to develop bacteria-powered fuel cells 2Basic research leads to a novel cancer therapy 2Basic research leads to a novel cancer therapy 3Basic research leads to a novel cancer therapy 4
WTAP Antibody...
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
...
Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Biology Products: